France DNA Vaccines Market

France DNA Vaccines Market Insights Forecasts to 2035

• The France DNA Vaccines Market Size Was Estimated at USD 280.7 Million in 2024
• The France DNA Vaccines Market Size is Expected to Grow at a CAGR of Around 8.02% from 2025 to 2035
• The France DNA Vaccines Market Size is Expected to Reach USD 655.7 Million by 2035

 

According to a research report published by Decision Advisor & Consulting, The France DNA Vaccines Market Size is Anticipated to reach USD 655.7 Million by 2035, Growing at a CAGR of 8.02% from 2025 to 2035. The France DNA vaccines market is driven by strong government support for vaccine R&D, growing focus on pandemic preparedness, advancements in biotechnology, and increasing demand for fast, scalable, and next-generation vaccine technologies.

 

Market Overview

The France DNA vaccines market refers to the segment of the pharmaceutical and biotechnology industry focused on the research, development, manufacturing, regulation, and commercialization of DNA-based vaccines in France, where plasmid DNA encoding specific antigens is administered to stimulate an immune response. This market encompasses activities by biopharmaceutical companies, research institutes, and healthcare organizations, supported by government funding and regulatory oversight, and targets applications such as infectious diseases, cancer immunotherapy, and emerging health threats, emphasizing innovation, safety, and rapid vaccine development.

 

France’s DNA vaccines market is shaped by public health needs and strategic innovation priorities. With a population of over 65 million, France continues to face significant challenges from infectious diseases and gaps in vaccination coverage despite large immunization campaigns. For example, France achieved vaccination coverage levels of around 77% during the COVID-19 rollout, reflecting both strong uptake and persistent hesitancy among segments of the population. This health landscape highlights growing demand for next-generation vaccine technologies, including DNA vaccines, which make up a portion of the 145 vaccines currently under development in the country’s robust biotech pipeline.

 

The France DNA vaccines market benefits from government support and funding aimed at strengthening vaccine innovation. The French government has allocated over €500 million in recent years to support vaccine research and broader vaccine technology development, positioning the country at the forefront of next-gen platforms like DNA and mRNA vaccines. This investment fuels R&D infrastructure, public-private collaborations, and national vaccination initiatives that aim to improve preventive care and epidemic preparedness. These conditions, strong public health demand, sizable R&D investment, and an active innovation ecosystem underscore the importance and growth potential of the DNA vaccines segment within France’s healthcare market.

 

Report Coverage

This research report categorizes the market for the France DNA vaccines market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France DNA vaccines market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France DNA vaccines market.

 

Driving Factors

The France DNA vaccines market is driven by strong government support for vaccine R&D, increasing focus on pandemic preparedness, and demand for next-generation vaccine technologies. Growth is further supported by France’s advanced biotechnology ecosystem and expanding research in genomics and immunotherapy.

 

Restraining Factors

The France DNA vaccines market faces restraints such as limited clinical validation compared to conventional vaccines, high R&D and clinical trial costs, and stringent regulatory requirements. Additionally, public vaccine hesitancy, long approval timelines, and competition from established mRNA and viral vector vaccines can slow adoption.

 

Market Segmentation

The France DNA vaccines market share is classified into technology, type, and application.

• The recombinant vaccines segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France DNA vaccines market is segmented by technology into recombinant vaccines and gene-based vaccines. Among these, the recombinant vaccines segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The recombinant vaccines segment is growing because of its proven safety, strong clinical evidence, established manufacturing processes, and higher regulatory acceptance compared to other DNA vaccine technologies in France.

 

• The preventive vaccines segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France DNA vaccines market is segmented by type into therapeutic vaccines and preventive vaccines. Among these, the preventive vaccines segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The preventive vaccines segment is growing because of high demand for disease prevention, government immunization programs, and increasing public awareness. Additionally, preventive DNA vaccines are widely adopted for infectious disease control, supported by strong R&D investment and regulatory backing in France.

 

• The infectious diseases segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France DNA vaccines market is segmented by application into oncology, infectious diseases, allergies, and others. Among these, the infectious diseases segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The infectious diseases segment is growing because of the high prevalence of viral and bacterial infections, the rising need for rapid and effective immunization, and strong government initiatives to enhance epidemic preparedness. Increasing investment in R&D for next-generation vaccines in France also supports the expansion of this segment.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France DNA vaccines market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Sanofi Pasteur
• Valneva SE
• Transgene S.A.
• Abivax
• OSE Immunotherapeutics
• Seqirus
• BioMérieux
• Genticel
• DNA Script
• Clean Cells
• Vaxinano
• Sanofi
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments:

• In April 2025, France launched the I?REIVAC?Emergence national vaccine research platform, backed by €12 million in funding under the France 2030 plan to accelerate clinical trials and evaluation of vaccines against emerging infectious diseases, strengthening national and academic?industrial collaboration in vaccinology.

 

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France DNA vaccines market based on the below-mentioned segments:

 

France DNA Vaccines Market, By Technology

• Recombinant vaccines
• Gene-based vaccines

 

France DNA Vaccines Market, By Type

• Therapeutic vaccines
• Preventive vaccines

 

France DNA Vaccines Market, By Application

• Oncology
• Infectious diseases
• Allergies
• Others

 

FAQ’s

1. What is the France DNA vaccines market size in 2024?

The France DNA vaccines market size was estimated at USD 280.7 million in 2024.

 

2. What is the projected market size of the France DNA vaccines market by 2035?

The France DNA vaccines market size is expected to reach USD 655.7 million by 2035.

 

3. What is the CAGR of the France DNA vaccines market?

The France DNA vaccines market size is expected to grow at a CAGR of around 8.02% from 2024 to 2035.

 

4. What are the key growth drivers of the France DNA vaccines market?

The France DNA vaccines market is driven by strong government support for vaccine R&D, growing focus on pandemic preparedness, advancements in biotechnology, and increasing demand for fast, scalable, and next-generation vaccine technologies.

 

5. Which type segment dominated the market in 2024?

The preventive vaccines segment dominated the market in 2024.

 

6. What segments are covered in the France DNA vaccines market report?

The France DNA Vaccines market is segmented on the basis of technology, type, and application.

 

7. Who are the key players in the France DNA vaccines market?

Key companies include Sanofi Pasteur, Valneva SE, Transgene S.A., Abivax, OSE Immunotherapeutics, Seqirus, BioMérieux, Genticel, DNA Script, Clean Cells, Vaxinano, Sanofi, and others.

 

8. Who are the target audiences for this market report?

The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).